Lung fibrosis (WP3624)

Homo sapiens

Authors

Friederike Ehrhart , Penny Nymark , Linda Rieswijk , Kristina Hanspers , Jonathan Mélius , Egon Willighagen , and Martina Summer-Kutmon

Activity

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

• Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor (2022).
• Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients (2022).
• AMP5A modulates Toll-like receptors 7 and 8 single-stranded RNA immune responses in PMA-differentiated THP-1 and PBMC (2022).
• Disrupting biological sensors of force promotes tissue regeneration in large organisms (2021).
• Transcriptomic changes in peripheral blood mononuclear cells with weight loss: systematic literature review and primary data synthesis (2021).
• A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection (2020).
• LMWF5A suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC (2020).
• Citalopram-induced pathways regulation and tentative treatment-outcome-predicting biomarkers in lymphoblastoid cell lines from depression patients (2020).
• Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale (2020).
• Linking Bisphenol S to Adverse Outcome Pathways Using a Combined Text Mining and Systems Biology Approach (2019).
• Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes (2018).
• GediNET for discovering gene associations across diseases using knowledge based machine learning approach (2022).
• A Data Fusion Pipeline for Generating and Enriching Adverse Outcome Pathway Descriptions.
• Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT (2023).

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Adverse Outcome Pathways Diseases Nanomaterials Pathways

Annotations

Pathway Ontology

respiratory system disease pathway carbon nanotube response pathway

Disease Ontology

pulmonary fibrosis

References

1. The chondrocyte, architect of cartilage. Biomechanics, structure, function and molecular biology of cartilage matrix macromolecules. Muir H. Bioessays. 1995 Dec;17(12):1039–48. PubMed Europe PMC Scholia
2. Mechanisms of actin stress fibre assembly. Naumanen P, Lappalainen P, Hotulainen P. J Microsc. 2008 Sep;231(3):446–54. PubMed Europe PMC Scholia
3. Molecular and cellular mechanisms of pulmonary fibrosis. Todd NW, Luzina IG, Atamas SP. Fibrogenesis Tissue Repair. 2012 Jul 23;5(1):11. PubMed Europe PMC Scholia
4. GeneMANIA: Fast gene network construction and function prediction for Cytoscape. Montojo J, Zuberi K, Rodriguez H, Bader GD, Morris Q. F1000Res. 2014 Jul 1;3:153. PubMed Europe PMC Scholia
5. The Comparative Toxicogenomics Database’s 10th year anniversary: update 2015. Davis AP, Grondin CJ, Lennon-Hopkins K, Saraceni-Richards C, Sciaky D, King BL, et al. Nucleic Acids Res. 2015 Jan;43(Database issue):D914-20. PubMed Europe PMC Scholia
6. Mechanisms of lung fibrosis induced by carbon nanotubes: towards an Adverse Outcome Pathway (AOP). Vietti G, Lison D, van den Brule S. Part Fibre Toxicol. 2016 Feb 29;13:11. PubMed Europe PMC Scholia
7. Nano-risk Science: application of toxicogenomics in an adverse outcome pathway framework for risk assessment of multi-walled carbon nanotubes. Labib S, Williams A, Yauk CL, Nikota JK, Wallin H, Vogel U, et al. Part Fibre Toxicol. 2016 Mar 15;13:15. PubMed Europe PMC Scholia
8. A Data Fusion Pipeline for Generating and Enriching Adverse Outcome Pathway Descriptions. Nymark P, Rieswijk L, Ehrhart F, Jeliazkova N, Tsiliki G, Sarimveis H, et al. Toxicol Sci. 2018 Mar 1;162(1):264–75. PubMed Europe PMC Scholia